MedTrace Logo

Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia

NCT00827840 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2011-12-23

No results posted yet for this study

Summary

Primary objective: To examine whether the switch to paliperidone ER from risperidone improves cognitive function in stabilized patients with schizophrenia.

Secondary objectives: To compare the general clinical outcomes (efficacy and safety) after switching to paliperidone ER from risperidone

Conditions

Interventions

DRUG

Paliperidone ER

3mg to 12mg of Paliperidone ER once a day

DRUG

Risperidone

1 to 6 mg of risperidone once or twice a day

Sponsors & Collaborators

  • Janssen Korea, Ltd., Korea

    collaborator INDUSTRY

  • Ministry of Health, Republic of Korea

    collaborator OTHER_GOV

  • Chonnam National University Hospital

    lead OTHER

Principal Investigators

  • Jin-Sang Yoon, Professor · Dept. of Psychiatry, Chonnam National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00827840 on ClinicalTrials.gov